Revvity (RVTY) said Friday the Food and Drug Administration has cleared EUROIMMUN's automated chemiluminescence-based immunoassay test, which is used for measuring free testosterone levels.
The test is the first FDA-cleared assay for direct measurement of free testosterone in human serum or plasma, the company said.
Revvity said that the test delivers results in 48 minutes with a output of nearly 60 tests per hour.
The assay is designed to diagnose androgen disorders, including hypogonadism, impotence, and polycystic ovarian syndrome, Revvity said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。